Primarily focused on cancer, neuronal
degeneration and immunological diseases, Helios Biosciences is your
partner to help you to streamline your Drug Discovery
process thanks to a unique technology integrating the
dynamic dimension of biological processes. Helios
develops a variety of offers to help the
identification and characterization of therapeutic
targets and biomarkers:
SIMPATHWAY (Smart Integrated Molecular
Pathway) is a curated, directed and annotated molecular
interaction network of intracellular signal transduction, delivered as
a database that also includes query and data representation software.
PROPAGAPATH (Signal Propagation Analysis
in Pathways) reveals the main molecular pathways involved in the
physio-pathological processes of interest.
DYNAPATH:
Helios Biosciences offers a new paradigm in systems biology: by introducing
the dynamic dimension in the study of biological regulatory pathways,
accurate therapeutic targets are characterized.
Take an analogy with car traffic. SIMPATHWAY would be a geographic
map linking cities, PROPAGAPATH would highlight the most used roads
during specific events, DYNAPATH would dynamically analyse the
consequences of accidents (pathology) or aid services (cures) on the
traffic.
Tissue & cell
expression: Helios BioSciences' know-how and 30 years of expertise
have enabled our company to optimize mRNA and protein expression
analyses, using fast and cost-efficient techniques. Helios BioSciences
caters from experimental scheme design to result interpretation and
ready-to-publish pictures.
June 2011
Meet us in Washington during BIO 2011. Visit us on our booth (hosted by the competitiveness bio-cluster Medicen) , request a meeting during the Bio Business Forum or attend the Fast-Track session organized by the French competitiveness clusters.
A publication describing our technology and its use in an european community founded program (FP6: VALAPODYN): Pubmed 20459389.
May 2010
BIO 2010 :
After attending BIoEurope Spring, we will attend BIO 2010 in Chicago. We will be happy to meet you at the French Pavillion (#3712) or during the Bio Business Forum.
March 2010
Immunosupressive drug targets :
We have finalized the experimental validation of 3 of the 6 immunosupressive targets that we have selected. This confirms the immunosuppressive potential of these targets.
Testimonies I warmly recommend resorting to Helios BioSciences for any operation of mRNA detection in the brain as well as in other tissues. Their professionalism, their know-how, their dynamism, their customer care and adaptability make them now indispensable collaborators."
Bruno Giros, PhD, Director of the INSERM Research Department U-513, "Neurobiology and Psychiatry"
The primary roadblock in exploring neuromuscular junctions is their relatively small size (~50nm). Helios has certainly shown that it is capable of overcoming barriers and exploring new grounds in science through dedication and persistence."
Javad Nazarian, M.S., The Children's National Medical Center, Washington DC.
